Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Next Generation Immunotherapies Market?
The market size of next-generation immunotherapies has experienced significant expansion in the past few years. It’s forecasted to grow from $133.81 billion in 2024 to a whopping $150.54 billion in 2025, with a compound annual growth rate (CAGR) of 12.5%. Factors contributing to this historic growth include the increasing prevalence of cancer, heightened investment in research and development, growth in government initiatives, increased health-related government spending, and the broadening of indications.
What Growth Rate Is Forecasted for the Next Generation Immunotherapies Market by 2029?
The market size of next-generation immunotherapies is predicted to experience swift expansion in the upcoming years, eventually reaching a valuation of $238.04 billion in 2029, with a compound annual growth rate of 12.1%. This projected growth during the forecast period can be attributed to several factors such as increasing cases of cancer, growing healthcare expenditure, rising adoption of chimeric antigen receptor (CAR) t-cell therapy, the heightened burden of chronic diseases, and the rising research efforts in next generation drug development. The impending period will see key trends such as a shift towards combination therapies, technological advancements in the field, innovative therapeutic approaches, progress in personalized medicine, and advanced regulatory support.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
Which Key Companies Are Shaping the Future of the Next Generation Immunotherapies Market?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
Which Factors Are Driving Demand in the Next Generation Immunotherapies Industry?
The growing number of cancer cases is anticipated to drive the expansion of the next-generation immunotherapies market in the future. Cancer, a collection of diseases marked by the unregulated proliferation and distribution of abnormal cells in the body, is increasing due to reasons such as aging populations, changes in lifestyle, exposure to environmental factors, and better detection techniques. Next-generation immunotherapies offer superior, targeted therapies that strengthen the body’s immune reaction to cancer, providing improved effectiveness, longevity, and customization. For example, May 2024 reports by the US-based government agency, the National Cancer Institute (NCI), showed that in 2022 approximately 20 million fresh cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Predictions for 2040 estimate 29.9 million new cases and 15.3 million cancer-associated deaths. Hence, the rising incidence of cancer is fueling the advancement of the next-generation immunotherapies market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp
How Is the Next Generation Immunotherapies Market Segmented by Several Divisions?
The next generation immunotherapies market covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates – ADC’s, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC’s): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors
What are the Emerging Market Trends Driving the Growth of the Next Generation Immunotherapies Industry?
Leading corporations in the next-generation immunotherapies market are concentrating on creating novel treatments such as CAR T-cell therapy, to battle diseases like cancer, autoimmune disorders, and infectious diseases. In this distinct type of immunotherapy, a patient’s T cells (an immune cell variant) are genetically modified to manifest chimeric antigen receptors (CARs). One such example is Immuneel Therapeutics Private Limited, a cell and gene therapy newcomer based in India, which in January 2025, introduced Qartemi, the first CAR T-cell therapy in India. This treatment, designed for adult B-cell non-Hodgkin lymphoma, employs genetically altered patient immune cells to seek out and eradicate cancer cells, thus providing a highly effective, tailor-made treatment solution. It offers a fresh chance of recovery for patients who have not responded well to traditional treatments, at a lower cost than comparable international alternatives.
Access The Full Report Here:
Which Regions Are Driving Growth in the Next Generation Immunotherapies Market?
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21231
This Report Delivers Insight On:
1. How big is the next generation immunotherapies market, and how is it changing globally?
2. Who are the major companies in the next generation immunotherapies market, and how are they performing?
3. What are the key opportunities and risks in the next generation immunotherapies market right now?
4. Which products or customer segments are growing the most in the next generation immunotherapies market?
5. What factors are helping or slowing down the growth of the next generation immunotherapies market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model